Show simple item record

dc.contributor.authorBaar, Marjolein P.
dc.contributor.authorPerdiguero, Eusebio
dc.contributor.authorMunoz-Canoves, Pura 
dc.contributor.authorde Keizer, Peter L. J.
dc.date.accessioned2018-11-05T11:58:22Z
dc.date.available2018-11-05T11:58:22Z
dc.date.issued2018
dc.identifierISI:000438324100023
dc.identifier.citationCurr Opin Pharmacol. 2018; 40:147-155
dc.identifier.issn1471-4892
dc.identifier.urihttp://hdl.handle.net/20.500.12105/6580
dc.description.abstractAging is the prime risk factor for the broad-based development of diseases. Frailty is a phenotypical hallmark of aging and is often used to assess whether the predicted benefits of a therapy outweigh the risks for older patients. Senescent cells form as a consequence of unresolved molecular damage and persistently secrete molecules that can impair tissue function. Recent evidence shows senescent cells can chronically interfere with stem cell function and drive aging of the musculoskeletal system. In addition, targeted apoptosis of senescent cells can restore tissue homeostasis in aged animals. Thus, targeting cellular senescence provides new therapeutic opportunities for the intervention of frailty-associated pathologies and could have pleiotropic health benefits.
dc.description.sponsorshipThe authors acknowledge support for MB from Dutch Cancer Society Grant UMCIJ-7141 awarded to PdK, and for EP and PMC from ERC-2016-AdG-741966 (STEM-AGING), SAF2015-67369-R, MDA and AFM. The DCESX/UPF is recipient of a `Maria de Maeztu' Program for Units of Excellence in R\&D MDM-2014-0370 (Government of Spain).
dc.language.isoeng
dc.publisherElsevier
dc.type.hasVersionVoR
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectMESENCHYMAL STEM-CELLS
dc.subjectSKELETAL-MUSCLE REGENERATION
dc.subjectMARROW STROMAL CELLS
dc.subjectCELLULAR SENESCENCE
dc.subjectSATELLITE CELLS
dc.subjectKNEE OSTEOARTHRITIS
dc.subjectARTICULAR-CARTILAGE
dc.subjectPROGENITOR CELLS
dc.subjectDNA-DAMAGE
dc.subjectPOSTTRAUMATIC OSTEOARTHRITIS
dc.titleMusculoskeletal senescence: a moving target ready to be eliminated
dc.typejournal article
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID29883814
dc.format.volume40
dc.format.page147-155
dc.identifier.doi10.1016/j.coph.2018.05.007
dc.contributor.funderDutch Cancer Society
dc.contributor.funderEuropean Commission
dc.contributor.funderMinisterio de Economía y Competitividad (España)
dc.contributor.funderEuropean Research Council
dc.description.peerreviewedSí
dc.identifier.e-issn1471-4973
dc.relation.publisherversionhttps://doi.org/10.1016/j.coph.2018.05.007
dc.identifier.journalCurrent Opinion in Pharmacology
dc.repisalud.orgCNICCNIC::Grupos de investigación::Laboratorio de Regeneración Tisular
dc.repisalud.institucionCNIC
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/SAF2015-67369-Res_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/H2020/741966es_ES
dc.rights.accessRightsopen accesses_ES


Files in this item

Acceso Abierto
Thumbnail
Name:
MusculoskeletalSenescenceMoving ...
Size:
853.9Kb
Format:
PDF
FilesOpen

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This item is licensed under a: Atribución 4.0 Internacional